Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lynk Pharmaceutical (Hangzhou) Co., Ltd.

https://en.lynkpharma.com/

Latest From Lynk Pharmaceutical (Hangzhou) Co., Ltd.

Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs

Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

Deal Watch Business Strategies

Lynk Pursues Own R&D Path But Partnerships Still Key

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

China Deals

Six Chinese Biotechs Bag $403m In Fresh Financing Rounds

In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.

China Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register